#United States #Orlando #AML #ImpriMed #xCellSense

ImpriMed to Present at the American Society of Hematology Annual Meeting

ImpriMed, a leading precision oncology contract research organization (CRO), has exciting news for the scientific community as it prepares to share significant findings on ex vivo drug sensitivity testing for acute myeloid leukemia (AML) at the upcoming 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. This prestigious event, taking place from December 6 to December 10, 2025, serves as a platform for the most recent advancements in hematology.

The company has been chosen to present two pivotal studies that emphasize the effectiveness of their innovative xCellSense® platform. This platform is designed to enhance the precision of drug sensitivity testing, enabling healthcare professionals to predict how individual patients will respond to specific treatments. According to ImpriMed’s CEO, Sungwon Lim, this opportunity to present at ASH underscores the validity of their platform in working alongside pharmaceutical partners and clinicians. Lim explains, "Our data suggests that integrating ex vivo functional testing with genomic profiling provides invaluable predictive insights into which AML patients are likely to respond positively to targeted therapies. By leveraging this synthesis of data, we are equipping drug developers and clinicians with the tools they need to optimize treatment approaches, innovate clinical trials, and enhance overall patient outcomes."

Key Research Findings

One prominent study that ImpriMed will discuss involves a prospective evaluation that fuses next-generation sequencing (NGS) genomic profiling with ex vivo drug sensitivity assessments involving 21 distinct drugs administered to AML patients under standard treatment regimens. The findings reveal a clear stratification of survival risks among AML patients, along with significant correlations between specific genotypes and drug efficacy. This crucial information validates the application of the xCellSense® platform in drug development, especially for candidate selection, patient enrichment strategies, and the creation of companion diagnostics that can guide therapeutic choices.

Additionally, ImpriMed plans to unveil their latest research on a quantitative analysis method for assessing ex vivo drug synergy, using primary samples sourced from AML patients. This cutting-edge analysis provides pharmaceutical companies with the capability to discern synergistic effects obtained from drug combinations, allowing them to accurately pinpoint patient subgroups that are most likely to benefit from multi-drug therapies.

Event Presentation Details

Oral Presentation

• - Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology
• - Date/Time: December 8, 2025, 3:15 PM - 3:30 PM
• - Publication Number: 939
• - Title: "Ex Vivo Drug Sensitivity Testing in Korean AML Patients: Integration of Functional and Genomic Profiles for Predicting Clinical Response and Survival"

Poster Presentation

• - Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology Poster III
• - Date/Time: December 8, 2025, 6:00 PM - 8:00 PM
• - Publication Number: 6137
• - Title: "Quantitative Ex Vivo Synergy Profiling Uncovers Heterogeneous Combination Responses in AML Primary Samples"

About ImpriMed

ImpriMed specializes in precision oncology through ex vivo drug sensitivity testing aimed primarily at hematologic malignancies. Its xCellSense® platform allows drug developers to evaluate drug candidates in live patient-derived cells, producing quantitative efficacy data and predictive biomarkers to minimize risks in clinical trials. Among the indications supported by the platform are acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. With laboratories located in Silicon Valley and Seoul, ImpriMed ensures both quality and compliance across its global operations. The company also collaborates with over 50 tertiary-care hospitals worldwide to maximize the impact of its research and findings.

For further information regarding ImpriMed's CRO services, please visit www.imprimedicine.com/cro.